Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LRMR
LARIMAR THERAPEUTICS, INC.
NASDAQ
$4.01
▼ DOWN 0.99% (-0.04)

KEY STATISTICS

Market Cap$416.57 M
52w High$6.42
52w Low$2.71
Dividend Yield—
Frequency—
P/E-2.06
Volume641.48K
Shares Out.103.88M

COMPANY

LEADERSHIP

Carole S. Ben-Maimon
CHIEF EXECUTIVE
Carole S. Ben-Maimon

COMPENSATION 2026

Salary$536,130
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$8,400
Total$3,236,560

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 19, 2014
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
71

PRICE TARGET

Target High$11.00
Target Low$5.00
Target Median$8.00
Target Consensus$8.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2020-05-29Reverse1:12

PRICE

$4.01 ▼ DOWN 0.99% (−$0.04)
OVERLAYS
$3.99$4.02$4.05$4.089:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.01

About Larimar Therapeutics, Inc.

https://www.larimartx.com ↗

Larimar Therapeutics, a clinical-stage biotech in Pennsylvania, develops treatments for rare diseases using cell-penetrating peptides, with its lead candidate CTI-1601 in Phase 1 for Friedreich's ataxia.

INDUSTRY

Biotechnology

A PRODUCT LARIMAR THERAPEUTICS, INC. IS KNOWN FOR

Nomlabofusp (CTI-1601)
Nomlabofusp (CTI-1601)

Nomlabofusp is a Phase 2 fusion protein therapy by Larimar that delivers human frataxin to mitochondria to treat Friedreich's ataxia, addressing its root cause.

COMPETITORS

COMPETITOR
BIIB COMPARE
IONS COMPARE
LXEO COMPARE
PTCT COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
70
LISTED HERE
12
RANKED BY POSITION SIZE
VTI
0.00% · 2.2M
IWM
0.01% · 1.7M
FESM
0.06% · 933.8K
DFAS
0.01% · 340.8K
R2US.L
0.01% · 149.0K
FSCC
0.12% · 96.3K
OMFS
0.13% · 93.5K
XRS2.DE
0.01% · 56.1K
RSSL
0.01% · 31.6K
AVSC
0.00% · 18.0K
BIB
0.01% · 3.7K
RESM
0.01% · 100

INSTITUTIONAL OWNERSHIP

SHARES OWNED
77.15%
HOLDERS
198
TOP 12 OF 198 · RANKED BY POSITION SIZE
Deerfield Management Company, L.P. (Series C)
35.6M sh · $160.23M
Blue Owl Capital Holdings LP
7.1M sh · $32.04M
Ra Capital Management, L.P.
6.0M sh · $19.53M
Millennium Management LLC
5.2M sh · $19.84M
Blackrock, Inc.
3.8M sh · $16.88M
Opaleye Management Inc.
3.7M sh · $10.56M
Chi Advisors LLC
3.4M sh · $13.49M
Blackrock Inc.
3.1M sh · $22.72M
Rtw Investments, LP
3.1M sh · $10.09M
Vanguard Group Inc
3.1M sh · $9.97M
Aigh Capital Management LLC
3.0M sh · $13.5M
Driehaus Capital Management LLC
2.9M sh · $13.2M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Hamilton Thomas Edward
Purchase · 50.0K shares
2026-07-06
★
DIRECTOR
SHERMAN JEFFREY W
Purchase · 55.1K shares
2026-05-19
★
DIRECTOR
Truitt Joseph
Purchase · 55.1K shares
2026-05-19
★
DIRECTOR
THOMAS FRANK E
Purchase · 55.1K shares
2026-05-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
BUY 1
4 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM Baird OUTPERFORM Citigroup BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ANRO$35.13COMPARE
ANNX$4.97COMPARE
ALT$3.11COMPARE
KYTX$8.37COMPARE
LXEO$4.86COMPARE
DBVT$13.54COMPARE
AMRN$13.97COMPARE
ACIU$2.65COMPARE